News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Adenosine Therapeutics Awarded SBIR Grant To Develop New Compounds For The Treatment Of Parkinson's Disease

10/19/2005 5:12:46 PM

CHARLOTTESVILLE, Va., Feb. 17 /PRNewswire/ -- Adenosine Therapeutics, LLC, a drug discovery and development company, announced today it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the Department of Health and Human Services at the National Institute of Health. The grant will fund the development and testing of novel A2A compounds for the treatment of Parkinson's disease. The amount of the award is $139,176.

The goals of the project are to identify and optimize compounds as therapeutic candidates for Parkinson's disease and to evaluate these novel A2A antagonist compounds in the laboratory. This project will be conducted in partnership with Dr. Jiang-Fan Chen at the Boston University School of Medicine.

"We anticipate that this grant will allow us to identify one or more clinical candidates for the treatment of Parkinson's disease. Our goal is to bring one of these new compounds into clinical trials," said Robert S. Capon, CEO and co-founder of Adenosine Therapeutics. "Long term, we are hopeful that this work will lead to more effective treatment for Parkinson's disease, a condition that affects over 1.5 million Americans."

About Adenosine Therapeutics

Adenosine Therapeutics focuses on the discovery and development of novel pharmaceutical products that target adenosine receptor subtypes. Candidates for drug development are identified and screened using the company's state-of- the-art adenosine receptor screening platform technology. The company was founded with the goal of taking new adenosine-receptor selective drugs into clinical trials for a broad range of potential indications. These drug indications include inflammatory indications, sepsis, heart attack, ischemia- reperfusion injury, vascular injury, spinal cord injury, COPD, asthma, diabetes, inflammatory bowel disease, retinopathy, epilepsy, Parkinson's disease, and site-specific angiogenesis. The company's most advanced drug development program is in Phase II clinical development. For more information on Adenosine Therapeutics, visit our web site at

Adenosine Therapeutics, LLC

CONTACT: Robert Capon of Adenosine Therapeutics, LLC, +1-434-220-9400,ext. 201

Read at

comments powered by Disqus